Clinical Report: Effects of Abiraterone and Enzalutamide on Hypokalemia

Overview

This systematic review and meta-analysis evaluates the risk of hypokalemia in prostate cancer patients treated with abiraterone and enzalutamide.

Background

Prostate cancer is a significant cause of morbidity and mortality in men, with novel therapies like abiraterone and enzalutamide associated with adverse effects, particularly electrolyte disturbances such as hypokalemia.

Data Highlights

No numerical data provided in the source material.

Key Findings

• Hypokalemia is a notable adverse effect of abiraterone and enzalutamide therapies.
• The incidence and severity of hypokalemia may vary based on the specific agent and disease stage.
• Abiraterone's mineralocorticoid-related effects are a known contributor to hypokalemia risk.
• Existing meta-analyses often do not differentiate between the risks associated with different ARAT regimens.

Clinical Implications

Clinicians should monitor prostate cancer patients receiving abiraterone or enzalutamide for signs of hypokalemia.

Conclusion

The systematic review highlights the importance of evaluating hypokalemia risk in patients treated with abiraterone and enzalutamide.

Related Resources & Content

1. Author(s)/Org, Source, Year -- Title
2. Author(s)/Org, Source, Year -- Title
3. Author(s)/Org, Source, Year -- Title
4. Author(s)/Org, Source, Year -- Title
5. Author(s)/Org, Source, Year -- Title
6. Author(s)/Org, Source, Year -- Title
7. FDA approves niraparib and abiraterone acetate plus prednisone for BRCA2-mutated metastatic castration-sensitive prostate cancer
8. FDA approves capivasertib with abiraterone and prednisone for PTEN-deficient androgen pathway modulation-naïve or -sensitive prostate cancer
9. Advanced and metastatic prostate cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up†
10. ASCO’s First Living Guideline in GU Cancers Reflects Recent Practice-Changing Trials on Systemic Treatment of mCRPC - The ASCO Post
11. https://www.jnjlabels.com/package-insert/product-monograph/prescribing-information/AKEEGA-pi.pdf
12. EAU Guidelines on Prostate Cancer - Follow-up - Uroweb
13. UGUPAVOABI_Protocol